FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 艾美疫苗股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06660 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 507,673,711 | RMB | | 1 RMB | | 507,673,711 | 因本公 ...

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing a surge, with companies like Ai Mei Vaccine gaining significant attention due to their stable performance and innovative technologies [1] Group 1: Company Performance - Ai Mei Vaccine reported steady revenue growth for the first half of 2025, with key innovative products nearing market launch, leading to expectations of improved performance and valuation [1][2] - The company has four major innovative products entering the market, including the 13-valent pneumococcal conjugate vaccine, which has a significant market potential in China, projected to exceed RMB 20 billion by 2030 [2][3] Group 2: Product Development - Ai Mei Vaccine is advancing in the rabies vaccine sector with multiple products, including a serum-free rabies vaccine and an mRNA rabies vaccine, positioning itself as a leader in a market expected to reach RMB 20 billion by 2030 [3] - The company holds 20 vaccine candidates in development across 12 disease areas, with 23 clinical approvals and 24 clinical trials ongoing, including seven innovative vaccines [3] Group 3: Market Potential and Valuation - The 13-valent pneumococcal conjugate vaccine is anticipated to capture a significant market share, with a penetration rate in China estimated at 25.9%, compared to over 80% in the U.S., indicating substantial growth opportunities [2] - DBS Bank's report suggests that Ai Mei Vaccine's current stock price is at the lower end of its peers' valuation range, with a projected fair target price of HKD 8.3 per share by 2026, indicating a potential upside of nearly 600% [4]

Group 1 - The Hong Kong stock market's innovative pharmaceutical sector has significantly outperformed the market since 2025, with 49 biopharmaceutical companies seeing stock price increases exceeding 100% [1] - Among the top 10 companies with the highest stock price increases, all have seen their prices multiply several times [1] - The recent listing of Zhonghui Biotech has catalyzed a bullish trend in multiple biopharmaceutical stocks, including vaccine stocks [1] Group 2 - Aimei Vaccine (06660) reported steady revenue in its half-year report for 2025, with major products entering the market and reduced R&D expenses [2] - The company has 20 vaccine products in development across 12 disease areas, with a pipeline covering the top ten global vaccine products [2] - Aimei's mRNA technology platform has received international recognition, with two major vaccine products approved for clinical trials in both China and the U.S. [2] Group 3 - Aimei is advancing several key vaccine products towards market launch, including the 13-valent pneumococcal conjugate vaccine and a serum-free rabies vaccine [3] - The 13-valent pneumococcal conjugate vaccine has a significant market potential, with a global shortfall of 180 million doses [3] - The serum-free rabies vaccine represents a major technological upgrade, enhancing safety and reducing adverse reactions [3] Group 4 - DBS Bank maintains an optimistic outlook for Aimei, projecting a 39% reduction in R&D expenses following the completion of major clinical trials in 2025 [4] - The company is expected to achieve profitability in 2026, with a projected annual sales growth rate of 45% from 2025 to 2027 [4] - Aimei's vaccines demonstrate superior efficacy compared to competitors, reinforcing the company's R&D capabilities and market position [4]

Group 1 - The Hong Kong innovative drug sector has significantly outperformed the market since 2025, with 49 pharmaceutical companies seeing stock price increases exceeding 100% [1] - The recent listing of Zhonghui Biotech has catalyzed a bullish trend in multiple biopharmaceutical stocks, including vaccine companies [1] - Chinese innovative drug companies are actively developing original innovative drugs, which are expected to create sustainable overseas opportunities [1] Group 2 - Aimee Vaccine (06660) reported stable revenue in its semi-annual report for the first half of 2025, with reduced R&D expenses and optimized operating costs [1] - The company has 20 vaccine products in development across 12 disease areas, with a pipeline covering the top ten global vaccine products [1] - Aimee has received clinical approval for two mRNA vaccines in both China and the U.S., validating its innovative capabilities and global market strategy [2] Group 3 - Aimee Vaccine is leading in the mRNA technology field, with its platform validated through extensive clinical trials, ensuring safety and efficacy [2] - The company has several key vaccine products nearing market launch, indicating an upcoming performance improvement [2] - The 13-valent pneumococcal conjugate vaccine is one of the broadest vaccines available, with a significant global market gap of 180 million doses [3] Group 4 - The innovative drug sector in Hong Kong is experiencing a new wave of development opportunities, with Aimee Vaccine positioned for rapid performance improvement due to its innovative vaccine R&D capabilities [4] - The company's stock price has strong upward momentum driven by industry growth and its improving fundamentals [4]

（於中華人民共和國註冊成立的股份有限公司） 股份代號：06660 中 期 報 告 2025 目 錄 | 公司資料 | 2 | | --- | --- | | 管理層討論及分析 | 5 | | 其他資料 | 30 | | 獨立審閱報告 | 41 | | 中期簡明綜合損益及其他全面收益表 | 42 | | 中期簡明綜合財務狀況表 | 43 | | 中期簡明綜合權益變動表 | 45 | | 中期簡明綜合現金流量表 | 46 | | 中期簡明綜合財務資料附註 | 48 | | 釋義 | 62 | 艾美疫苗股份有限公司 二零二五年中期報告 公司資料 執行董事 周延先生 周欣先生 賈紹君先生 關文先生 周杰先生 非執行董事 趙繼臣先生 王愛軍女士 （於2025年4月13日辭任） 獨立非執行董事 Ker Wei PEI教授 文潔女士 郭曉光先生 歐陽輝先生 (於2025年4月13日辭任） 監事 （自2025年5月20日起卸任） 宋廷鋒先生 （監事會主席） 馬倫先生 宋嘉帥先生 審計委員會 Ker Wei PEI教授 （主席） 歐陽輝先生 （於2025年4月13日辭任） 郭曉光先生 文潔女士 （於2025年4月17日獲委任為 ...

Core Viewpoint - The company, Ai Mei Vaccine, is poised for significant growth with the upcoming commercialization of key vaccine products and a reduction in R&D expenses, leading to a strong financial outlook for 2025 and beyond [1][2] Group 1: Financial Performance - Ai Mei Vaccine reported stable revenue for the first half of 2025, supported by the impending launch of four major vaccine products [1] - The company is expected to achieve profitability by 2026, with sales projected to grow at a compound annual growth rate (CAGR) of 45% from 2025 to 2027 [2] Group 2: Product Development - Four major vaccine products are nearing commercialization: - The registration application for the updated rabies vaccine has been accepted - The 13-valent pneumonia conjugate vaccine has applied for registration and completed on-site verification - The 23-valent pneumonia polysaccharide vaccine has completed Phase III clinical serum testing and is entering the statistical unblinding phase - The updated high-efficiency diploid rabies vaccine is in Phase III clinical trials, with a registration application expected in 2026 [1] - The company has 20 vaccine products in development across 12 disease areas, with 23 clinical approvals and 24 ongoing clinical trials, including 7 innovative Class 1 vaccines [1] Group 3: Market Expansion - Ai Mei Vaccine has successfully entered the African market with its quadrivalent meningococcal polysaccharide vaccine and is registering in Central Asia - The rabies vaccine has made its debut in the Central American market - The hepatitis B vaccine is actively undergoing registration processes in Southeast Asia, while the hepatitis A vaccine is progressing in South Asia [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 財務摘要 截 至6月30日止六個月 | | 2025年 | 2024年 | 變 動 | | --- | --- | --- | --- | | 主要收益表項目 | 人民幣千元 | 人民幣千元 | % | | 收 入 | 514,657 | 537,178 | -4.2 | | 毛 利 | 341,236 | 388,290 | -12.1 | | 母公司擁有人應佔虧損 | (131,116) | (139,254) | -5.8 | – 1 – 董事會欣然公佈本集團截至2025年6月30日止六個月的未經審計中期簡 明 綜 合 業 績，連 同 截 至2024年6月30日 止 六 個 月 的 可 比 較 數 據 載 列 如 下： 中期簡明綜合損益及其他全面收益表 截 至202 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 董事會會議通告 艾 美 疫 苗 股 份 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年8月27日（星 期 三）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及其附屬公司截至2025年6月30日 止 六 個 月 的 中 期 業 績 及 其 發 佈，並 考 慮 建 議 派 發 中 期 股 息（如 有），以 及 處 理 其 他 事 項。 承董事會命 艾美疫苗股份有限公司 董事會主席兼CEO 周延先生 香 港，2025年8月15日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 事 周 延 先 生、周 欣 先 生、賈 紹 君 先 生、 關 文 先 生 及 周 杰 先 生；非 執 行 董 事 趙 繼 臣 先 生；及 獨 立 ...

Group 1 - The core viewpoint of the report is that Aimei Vaccine (06660.HK) is expected to achieve profitability by 2026, which will lead to a revaluation of its stock price due to its leading position in the pneumonia and rabies vaccine segments [1][2] - Aimei Vaccine's current stock price is at a 56% discount compared to its peers' projected sales for 2026, indicating it is at the lower end of the valuation range among competitors [1] - The report predicts a significant reduction in R&D expenses by 39% after the completion of major clinical trials in 2025, contributing to the expected profitability in 2026 [1] Group 2 - Aimei Vaccine is anticipated to achieve a compound annual growth rate (CAGR) of 45% in sales from 2025 to 2027, driven by the expected launch of the 13-valent pneumococcal conjugate vaccine (PCV13) and a serum-free rabies vaccine [1] - The company is projected to capture approximately 20% and 10% market shares in the rabies and pneumonia vaccine markets in China by 2026, respectively [1] - Aimei's vaccines are reported to have superior efficacy compared to Pfizer's products, and the rabies vaccine's serum-free formulation is expected to result in fewer side effects [2] Group 3 - Aimei Vaccine's stock rose by 9.96% to close at HKD 5.74 per share, reflecting the ongoing enthusiasm for vaccine stocks in the Hong Kong market [2] - The report highlights the recent bullish trend in the Hong Kong innovative drug sector, exemplified by the significant market performance of Zhonghui Biotechnology-B, which saw its stock price increase by over 162% on its first trading day [2] - Multiple institutions have indicated that the Hong Kong innovative drug market is entering a bull market, suggesting that Aimei Vaccine will also experience a value revaluation as its fundamentals improve [2]

财务数据显示，截至2024年12月31日，艾美疫苗实现营业总收入12.85亿元，同比增长8.22%；归母净利 润-2.77亿元，同比增长78.69%；毛利率74.2%，资产负债率50.63%。 8月5日，截至港股收盘，恒生指数上涨0.68%，报24902.53点。艾美疫苗（06660.HK）收报5.03港元/ 股，上涨8.41%，成交量180.82万股，成交额888.37万港元，振幅9.7%。 最近一个月来，艾美疫苗累计涨幅21.47%，今年来累计跌幅24.43%，跑输恒生指数23.3%的涨幅。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为2.19倍，行业中值6.44倍。艾美疫苗市盈 率-19.01倍，行业排名第111位；其他精优药业（00858.HK）为1.42倍、金斯瑞生物科技（01548.HK） 为1.63倍、东瑞制药（02348.HK）为3.35倍、吉林长龙药业（08049.HK）为5.94倍、大健康国际 （02211.HK）为6.94倍。 资料显示，艾美疫苗股份有限公司是中国第二大疫苗公司,所占市场份额为7.4%,仅次於国有企业中国医 ...